Genmab A/S (NASDAQ:GMAB) Sets New 12-Month High – Time to Buy?

Genmab A/S Sponsored ADR (NASDAQ:GMAB)’s share price reached a new 52-week high during trading on Thursday. The company traded as high as $40.17 and last traded at $39.67, with a volume of 2,043,779 shares. The stock had previously closed at $39.57.

Analyst Ratings Changes

Several brokerages have recently commented on GMAB. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. HC Wainwright lifted their price target on Genmab A/S from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Guggenheim upped their price target on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and increased their price objective for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd. Finally, Truist Financial raised their price objective on shares of Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average price target of $43.39.

Genmab A/S Stock Up 9.5%

The firm’s 50-day moving average is $35.25 and its two-hundred day moving average is $30.21. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The stock has a market cap of $27.33 billion, a P/E ratio of 34.48, a PEG ratio of 1.84 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. On average, equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.22 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently added to or reduced their stakes in the company. Personal CFO Solutions LLC boosted its stake in Genmab A/S by 3.7% in the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after acquiring an additional 386 shares during the last quarter. Versant Capital Management Inc grew its holdings in Genmab A/S by 4.5% during the 3rd quarter. Versant Capital Management Inc now owns 12,235 shares of the company’s stock worth $436,000 after acquiring an additional 523 shares during the period. GAMMA Investing LLC grew its holdings in Genmab A/S by 16.4% during the 2nd quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock worth $109,000 after acquiring an additional 561 shares during the period. Summitry LLC raised its position in shares of Genmab A/S by 5.3% during the 1st quarter. Summitry LLC now owns 11,170 shares of the company’s stock valued at $300,000 after acquiring an additional 567 shares during the last quarter. Finally, AdvisorShares Investments LLC raised its position in shares of Genmab A/S by 2.2% during the 1st quarter. AdvisorShares Investments LLC now owns 30,853 shares of the company’s stock valued at $828,000 after acquiring an additional 653 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.